How is Re-Vana Using its Sustained-Delivery Hydrogel Technology to Position Itself as a Long-Term Partner at the 2026 J.P. Morgan Healthcare Conference?

Pharmaceutical Executive: How is Re-Vana using its sustained-delivery hydrogel technology to position itself as a long-term partner rather than a single-asset story at the 2026 J.P. Morgan Healthcare Conference?

Michael O’Rurke: Re-Vana has two core platform technologies, and one is called EyeLief and the other is OcuLeif. What makes Re-Vana unique is that we have demonstrated the delivery of biologics for six months or greater, with hydrogel, photo cross linked implants, biodegradable in the eye, with no surgery involved.

The big difference is that we use a light to prepare our implants, as opposed to heat so we don't destroy the biologics. We don't destroy the protein. The goal of the company is certainly not to be a single asset company, nor is it to be a drug delivery company. It's really important that we have a hybrid strategy involved here. So, the hybrid strategy says we're going to look at having our own internal assets, raise capital against that, and then take those products further forward into the market. But we have our second part of the strategy is our external collaborations. So, we work with major pharma companies. We take their assets, their therapeutics, bring them into Re-Vana and then test them on a feasibility type basis, or some other a contractual program to really validate their drug with their technology.

It means that we can offer companies with therapeutics, a means to deliver them on a sustained release basis, because we believe the future of ocular drug delivery and maybe other market segments, is really based on a sustained release basis. In our case it's all about reducing the treatment burden for patients, so patients don't have to get multiple injections over multiple months into the eye, but instead get one injection, let's say every six months is a primary goal of the company. So it's not a single asset group. It's looking at internal assets and building multiple external collaborations.